Allen Klee, an analyst from Maxim Group, reiterated the Buy rating on HEALWELL AI. The associated price target is C$5.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Allen Klee has given his Buy rating due to a combination of factors influencing HEALWELL AI’s recent performance and future prospects. The company’s impressive 2Q25 results, with a significant revenue increase of 645% year-over-year and achieving its first positive adjusted EBITDA, demonstrate strong financial growth. This growth is largely attributed to the transformational acquisition of Orion Health and other strategic acquisitions, which have bolstered the company’s healthcare software and AI capabilities.
Moreover, HEALWELL AI’s management has maintained a positive outlook for continued growth, projecting 100% year-over-year growth in the AI and Data Science segment. The company’s strategic focus on divesting non-core segments to concentrate on digital SaaS and services further aligns with its growth strategy. Additionally, the company’s financial position, with C$19.1M in cash, supports its organic growth plans, although further acquisitions may require additional capital. These factors, along with a 10-year DCF analysis supporting a C$5.00 price target, underpin Klee’s Buy rating.
In another report released yesterday, Stifel Nicolaus also maintained a Buy rating on the stock with a C$3.80 price target.
AIDX’s price has also changed moderately for the past six months – from C$1.700 to C$1.450, which is a -14.71% drop .